Literature DB >> 10793075

Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity.

R E Wilentz1, M Goggins, M Redston, V A Marcus, N V Adsay, T A Sohn, S S Kadkol, C J Yeo, M Choti, M Zahurak, K Johnson, M Tascilar, G J Offerhaus, R H Hruban, S E Kern.   

Abstract

Medullary carcinomas of the pancreas are a recently described, histologically distinct subset of poorly differentiated adenocarcinomas that may have a unique pathogenesis and clinical course. To further evaluate these neoplasms, we studied genetic, pathological, and clinical features of 13 newly identified medullary carcinomas of the pancreas. Nine (69%) of these had wild-type K-ras genes, and one had microsatellite instability (MSI). This MSI medullary carcinoma, along with three previously reported MSI medullary carcinomas, were examined immunohistochemically for Mlh1 and Msh2 expression, and all four expressed Msh2 but did not express Mlh1. In contrast, all of the medullary carcinomas without MSI expressed both Msh2 and Mlh1. Remarkably, the MSI medullary carcinoma of the pancreas in the present series arose in a patient with a synchronous but histologically distinct cecal carcinoma that also had MSI and did not express Mlh1. The synchronous occurrence of two MSI carcinomas suggests an inherited basis for the development of these carcinomas. Indeed, the medullary phenotype, irrespective of MSI, was highly associated with a family history of cancer in first-degree relatives (P < 0.001). Finally, one medullary carcinoma with lymphoepithelioma-like features contained Epstein-Barr virus-encoded RNA-1 by in situ hybridization. Therefore, because of medullary carcinoma's special genetic, immunohistochemical, and clinical features, recognition of the medullary variant of pancreatic adenocarcinoma is important. Only by classifying medullary carcinoma as special subset of adenocarcinoma can we hope to further elucidate its unique pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10793075      PMCID: PMC1876921          DOI: 10.1016/S0002-9440(10)65035-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

Authors:  M Goggins; M Schutte; J Lu; C A Moskaluk; C L Weinstein; G M Petersen; C J Yeo; C E Jackson; H T Lynch; R H Hruban; S E Kern
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

2.  Epstein-Barr virus-associated gastric carcinoma in Mexico: analysis of 135 consecutive gastrectomies in two hospitals.

Authors:  R Herrera-Goepfert; E Reyes; M Hernández-Avila; A Mohar; R Shinkura; C Fujiyama; S Akiba; Y Eizuru; Y Harada; M Tokunaga
Journal:  Mod Pathol       Date:  1999-09       Impact factor: 7.842

3.  Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers.

Authors:  G H Su; R H Hruban; R K Bansal; G S Bova; D J Tang; M C Shekher; A M Westerman; M M Entius; M Goggins; C J Yeo; S E Kern
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

4.  Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing.

Authors:  S Syngal; E A Fox; C Li; M Dovidio; C Eng; R D Kolodner; J E Garber
Journal:  JAMA       Date:  1999-07-21       Impact factor: 56.272

5.  BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications.

Authors:  M Goggins; R H Hruban; S E Kern
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

Review 6.  Genetics of pancreatic cancer. From genes to families.

Authors:  R H Hruban; G M Petersen; P K Ha; S E Kern
Journal:  Surg Oncol Clin N Am       Date:  1998-01       Impact factor: 3.495

Review 7.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

Review 8.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

Authors:  R H Hruban; A D van Mansfeld; G J Offerhaus; D H van Weering; D C Allison; S N Goodman; T W Kensler; K K Bose; J L Cameron; J L Bos
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

9.  High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.

Authors:  K Grünewald; J Lyons; A Fröhlich; H Feichtinger; R A Weger; G Schwab; J W Janssen; C R Bartram
Journal:  Int J Cancer       Date:  1989-06-15       Impact factor: 7.396

10.  Systemic cancer and the FAMMM syndrome.

Authors:  W Bergman; P Watson; J de Jong; H T Lynch; R M Fusaro
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more
  78 in total

Review 1.  Genetic progression in the pancreatic ducts.

Authors:  R H Hruban; R E Wilentz; S E Kern
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 2.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

3.  A woman with remotely treated pancreas cancer and new abdominal pain: a discussion of evaluation and management.

Authors:  Andrew S Epstein; Eileen M O'Reilly; Maeve Lowery; Ali Shamseddine; Jinru Shia; Sally Temraz; Ashwaq Al-Olayan; Mohamed Naghy; David Kelsen; Manish A Shah; Ghassan K Abou-Alfa
Journal:  J Gastrointest Cancer       Date:  2011-12

Review 4.  Hereditary pancreatic cancer.

Authors:  Shilpa Grover; Sapna Syngal
Journal:  Gastroenterology       Date:  2010-08-19       Impact factor: 22.682

5.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.

Authors:  Nabeel Bardeesy; Kuang-Hung Cheng; Justin H Berger; Gerald C Chu; Jessica Pahler; Peter Olson; Aram F Hezel; James Horner; Gregory Y Lauwers; Douglas Hanahan; Ronald A DePinho
Journal:  Genes Dev       Date:  2006-11-15       Impact factor: 11.361

6.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

7.  [Ulcerating tumor in the duodenum and head of the pancreas].

Authors:  W Wild; G Mall; T Balci; P Hödl; P Dörr; M H M Schwarzbach
Journal:  Chirurg       Date:  2013-12       Impact factor: 0.955

Review 8.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

Review 9.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

10.  Intraductal papillary mucinous neoplasm of the pancreas with loss of mismatch repair in a patient with Lynch syndrome.

Authors:  Jennifer A Sparr; Prathap Bandipalliam; Mark S Redston; Sapna Syngal
Journal:  Am J Surg Pathol       Date:  2009-02       Impact factor: 6.394

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.